Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. more
Time Frame | ARGX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.74% | -2.12% | -3% |
1-Month Return | 5.41% | -3.42% | -0.73% |
3-Month Return | 17.04% | -11.13% | 2.87% |
6-Month Return | 60.83% | -5.74% | 7.17% |
1-Year Return | 84.07% | 3.97% | 25.31% |
3-Year Return | 84.83% | 1.05% | 28.38% |
5-Year Return | 285.07% | 34.37% | 81.89% |
10-Year Return | 2612.26% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 78.17M | 44.85M | 497.28M | 410.75M | 1.23B | [{"date":"2019-12-31","value":6.37,"profit":true},{"date":"2020-12-31","value":3.66,"profit":true},{"date":"2021-12-31","value":40.55,"profit":true},{"date":"2022-12-31","value":33.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 196.82M | 303.93M | 510.04M | 29.43M | 117.83M | [{"date":"2019-12-31","value":38.59,"profit":true},{"date":"2020-12-31","value":59.59,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":5.77,"profit":true},{"date":"2023-12-31","value":23.1,"profit":true}] |
Gross Profit | (118.65M) | (259.08M) | (12.77M) | 381.31M | 1.11B | [{"date":"2019-12-31","value":-10.7,"profit":false},{"date":"2020-12-31","value":-23.37,"profit":false},{"date":"2021-12-31","value":-1.15,"profit":false},{"date":"2022-12-31","value":34.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (151.78%) | (577.68%) | (2.57%) | 92.83% | 90.39% | [{"date":"2019-12-31","value":-163.5,"profit":false},{"date":"2020-12-31","value":-622.26,"profit":false},{"date":"2021-12-31","value":-2.77,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.37,"profit":true}] |
Operating Expenses | 279.41M | 562.36M | 846.02M | 1.10B | 1.53B | [{"date":"2019-12-31","value":18.22,"profit":true},{"date":"2020-12-31","value":36.67,"profit":true},{"date":"2021-12-31","value":55.17,"profit":true},{"date":"2022-12-31","value":71.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (200.01M) | (514.38M) | (348.75M) | (719.66M) | (425.05M) | [{"date":"2019-12-31","value":-20001120172,"profit":false},{"date":"2020-12-31","value":-51437686300,"profit":false},{"date":"2021-12-31","value":-34874600000,"profit":false},{"date":"2022-12-31","value":-71966300000,"profit":false},{"date":"2023-12-31","value":-42504900000,"profit":false}] |
Total Non-Operating Income/Expense | 30.54M | (129.28M) | (35.95M) | 18.72M | 212.61M | [{"date":"2019-12-31","value":14.36,"profit":true},{"date":"2020-12-31","value":-60.81,"profit":false},{"date":"2021-12-31","value":-16.91,"profit":false},{"date":"2022-12-31","value":8.81,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (177.23M) | (647.81M) | (399.74M) | (729.31M) | (304.50M) | [{"date":"2019-12-31","value":-17722578188,"profit":false},{"date":"2020-12-31","value":-64780711000,"profit":false},{"date":"2021-12-31","value":-39974300000,"profit":false},{"date":"2022-12-31","value":-72931400000,"profit":false},{"date":"2023-12-31","value":-30449600000,"profit":false}] |
Income Taxes | 5.32M | 3.43M | 8.52M | (19.72M) | (9.44M) | [{"date":"2019-12-31","value":62.46,"profit":true},{"date":"2020-12-31","value":40.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-231.4,"profit":false},{"date":"2023-12-31","value":-110.81,"profit":false}] |
Income After Taxes | (182.55M) | (651.23M) | (408.26M) | (709.59M) | (295.05M) | [{"date":"2019-12-31","value":-18254883888,"profit":false},{"date":"2020-12-31","value":-65123490112,"profit":false},{"date":"2021-12-31","value":-40826500000,"profit":false},{"date":"2022-12-31","value":-70959400000,"profit":false},{"date":"2023-12-31","value":-29505300000,"profit":false}] |
Income From Continuous Operations | (162.97M) | (528.92M) | (408.26M) | (709.59M) | (295.05M) | [{"date":"2019-12-31","value":-16296500000,"profit":false},{"date":"2020-12-31","value":-52892300000,"profit":false},{"date":"2021-12-31","value":-40826500000,"profit":false},{"date":"2022-12-31","value":-70959400000,"profit":false},{"date":"2023-12-31","value":-29505300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (182.55M) | (651.23M) | (408.26M) | (709.59M) | (295.05M) | [{"date":"2019-12-31","value":-18254883950,"profit":false},{"date":"2020-12-31","value":-65123490200,"profit":false},{"date":"2021-12-31","value":-40826500000,"profit":false},{"date":"2022-12-31","value":-70959400000,"profit":false},{"date":"2023-12-31","value":-29505300000,"profit":false}] |
EPS (Diluted) | (4.23) | (11.65) | (7.85) | (13.12) | (5.33) | [{"date":"2019-12-31","value":-423,"profit":false},{"date":"2020-12-31","value":-1165,"profit":false},{"date":"2021-12-31","value":-785,"profit":false},{"date":"2022-12-31","value":-1312,"profit":false},{"date":"2023-12-31","value":-533,"profit":false}] |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ARGX | |
---|---|
ROA (LTM) | -5.51% |
ROE (LTM) | -5.74% |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ARGX | |
---|---|
Trailing PE | NM |
Forward PE | 104.17 |
P/S (TTM) | 20.06 |
P/B | 8.78 |
EV/R | 18.60 |
EV/Ebitda | NM |
PEG | NM |
argenx NV ADR (ARGX) share price today is $623.82
Yes, Indians can buy shares of argenx NV ADR (ARGX) on Vested. To buy argenx NV ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of argenx NV ADR (ARGX) via the Vested app. You can start investing in argenx NV ADR (ARGX) with a minimum investment of $1.
You can invest in shares of argenx NV ADR (ARGX) via Vested in three simple steps:
The 52-week high price of argenx NV ADR (ARGX) is $644.97. The 52-week low price of argenx NV ADR (ARGX) is $349.86.
The price-to-earnings (P/E) ratio of argenx NV ADR (ARGX) is
The price-to-book (P/B) ratio of argenx NV ADR (ARGX) is 8.78
The dividend yield of argenx NV ADR (ARGX) is 0.00%
The market capitalization of argenx NV ADR (ARGX) is $37.73B
The stock symbol (or ticker) of argenx NV ADR is ARGX